Mercer Global Advisors
BMY.RT

Mercer Global Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Mercer Global Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,018
Closed -$7K – 1698
2020
Q4 		$7K Buy
10,018
+4
+0% +$9 ﹤0.01% 1346
2020
Q3 		$23K Buy
+10,014
New +$28.6K ﹤0.01% 1226
2020
Q2 		– Sell
-14,308
Closed -$54K – 1216
2020
Q1 		$54K Buy
+14,308
New +$47.1K ﹤0.01% 1043

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Mercer Global Advisors's BMY.RT Position: Q1 2021 in Review

Mercer Global Advisors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 10,018 shares — an estimated $7K sold.

Mercer Global Advisors first reported a position in BMY.RT in Q1 2020 and held it in 3 quarters. The position peaked at $54K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Mercer Global Advisors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Mercer Global Advisors sold 10,018 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $7K.
  • Mercer Global Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 3 quarters.
  • Mercer Global Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $54K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Mercer Global Advisors's 13F filing for Q1 2021, filed 11 May 2021.